Oncimmune inks distribution deal for lung cancer test in Portugal

Personalised immunodiagnostics developer Oncimmune Holdings has signed an exclusive agreement for the distribution of its ‘EarlyCDT-Lung’ test kit in Portugal with Sabartech, its existing distributor in Spain, it announced on Friday.

The AIM-traded company said the agreement included a minimum sales commitment of £0.7m over five years.

It said that every year in Portugal, around 5,300 new cases were diagnosed and approximately 4,700 deaths occurred from lung cancer.

Lung cancer remained the largest cause of cancer-related deaths in the country.

Oncimmune said it had also extended Sabartech's agreement in Spain from three to five years, in light of the “excellent progress” made there - including the recently-secured agreement to sell EarlyCDT-Lung as a screening test for the early detection of lung cancer through the hospitals and clinics of the Quirónsalud group.

The extension added a further £1.8m of minimum sales commitments over years four and five.

“Portugal and Spain are important European markets and Sabartech has made good progress so far including selling EarlyCDT-Lung for screening through Quirónsalud, the largest private hospital network in Spain,” said Oncimmune chief executive officer Dr Adam Hill.

“Extending our relationship to include Portugal was a natural progression and marks another step in the commercialisation of EarlyCDT-Lung.”